DALLAS, May 18 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC:AKCA) (BULLETIN BOARD: AKCA) today announced that its common stock is trading on the OTC Bulletin Board under the trading symbol AKCA.OB. Access Pharmaceuticals, Inc. is an emerging pharmaceutical company developing unique polymer linked cytotoxics for use in the treatment of cancer. Its lead product AP5346 is in Phase II clinical testing. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission. DATASOURCE: Access Pharmaceuticals, Inc. CONTACT: Stephen B. Thompson, Vice President & CFO of Access Pharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C. Weinberger of Wolfe Axelrod Weinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.

Copyright